Thrombotic microangiopathy is a well-known heterogeneous disorder that occurs as a complication of allogenic bone marrow transplantation (BMT). We evaluated 12 consecutive patients receiving HLA-matched unrelated BMT and 12 consecutive recipients of HLAidentical related BMT for the development of bone marrow transplantation-associated thrombotic microangiopathy (BMT-TM) on days 30 and 60 following BMT. A diagnosis was made in four of 12 (33.3%) unrelated compared to none of 12 (0%) HLA-identical cases. Levels of serum lactic dehydrogenase (LDH), fibrin degraded products (FDP) and de novo thrombocytopenia were elevated in eight of 12 patients (66.7%) receiving unrelated donor BMT, and none of the patients receiving related donor BMT. Our findings suggest clinical or subclinical microangiopathic changes may occur frequently in unrelated donor BMT. FDP elevation is possibly an important marker of microangiopathic changes as early complications of BMT.
Bone marrow transplantation from HLA-identical donors has proved a useful therapy for a wide variety of hematological malignancies. In 1992, locating HLA-matched unrelated volunteer donors became possible with the development of the Japan Marrow Donor Program. 1 Although outcome of unrelated BMT has been improved by the use of molecular typing and intensive prophylaxis regimens, 2, 3 it does not compare well with that of related donor BMT.
The obstacles to successful BMT are the development of acute and chronic GVHD and other complications, one of which is thrombotic microangiopathy following BMT (BMT-TM), either hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP). 4, 5 BMT-TM has been described with a highly variable incidence in several series of both allogenic and autologous BMTs. 4 Various causative factors proposed include total body irradiation, acute GVHD, active cytomegalovirus or fungal Correspondence: T Natazuka, Shinseikai-Santoh Clinic, Ro336-85 Nagahisa, Nagahisa-cho, Oda-city, Shimane 694, Japan Received 4 August 1997; accepted 20 November 1997 infection, and cyclosporin A (CsA) toxicity, although no single specific factor has been identified. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] We have frequently observed BMT-TM in unrelated donor patients. 16 In the present study, we investigated coagulation abnormalities and BMT-TM by comparison of patients receiving related and unrelated donor BMT.
Materials and methods
The study group consisted of 12 consecutive recipients of unrelated donor BMT aged 17 to 50 years treated between January 1993 and October 1995 at Hyogo Medical Center for Adults, and 12 consecutive patients receiving related donor BMT during the same period. The characteristics of patients and donors are shown in Table 1 . Serological typing and molecular typing was done for unrelated donor/recipient matching. 1 Two preparative regimens were used as shown in Table 1 . Ex vivo marrow T cell depletion was not performed. All patients received a combination of CsA, MTX and prednisolone, as previously described. 17 Prednisolone treatment was begun on day 7 and given at a dose of 0.5 mg/kg intravenously and then at 0.5 mg/kg intravenously on day 15 for unrelated donor patients.
Thrombotic microangiopathy was defined by simultaneous occurrence of intravascular hemolysis characterized by appearance of nucleated cells and fragmented cells in peripheral blood and de novo thrombocytopenia. Intravascular hemolysis was diagnosed when a simultaneous rise in serum lactate dehydrogenase (LDH) levels and reticulocytes was associated with a decrease in hemoglobin levels.
Immune hemolysis was excluded by a negative Coombs test in all cases. 18 Thrombotic microangiopathy includes elevation of fibrin degraded products (FDP) with only minimal laboratory evidence of disseminated intravascular coagulation (DIC). FDP was measured by latex agglutination (FDPL test, Teikoku Zoki, Tokyo, Japan). Chemistry tests were determined on a Hitachi 736 (Tokyo, Japan) automated analyzer with a kit from Wako (Osaka, Japan). LDH was measured by the production of NADH with lactate as substrate, as recommended by IFCC (120-230 IU/l The numbers in parentheses are means ± s.e. CML = chronic myelogenous leukemia; CP = chronic phase; CR = complete remission; RAEB = refractory anemia with excess blasts; HAD = Hodgkin's disease; NHL = non-Hodgkin's lymphoma; TBI = total body irradiation; CY = cyclophosphamide; AraC = cytosine arabinocide; BUS = busulfan; VP-16 = etoposide; CsA = cyclosporin A; MTX = methotrexate; PSL = prednisolone.
groups were compared using Pearson's 2 test. All tests used an alpha level of 0.05 and a two-sided alternative hypothesis.
Results
The characteristics of patients are shown in Table 1 . In 10 of 12 related donor BMTs, patients received TBI/CY as conditioning, while in one case the patient received a TBT/AraC/CY regimen. Time from diagnosis to BMT in the unrelated group was longer than that in the related group. All 12 unrelated recipients received a TBI/AraC/CY regimen. Day of Ͼ1000/l WBCs was slightly delayed in unrelated BMT recipients. Day of 50 000/l platelets was significantly delayed in the unrelated group.
Microangiopathic changes after BMT
We compared hematological biochemical and hemostatic changes between the two groups on day 30 and 60 after BMT (Table 2) . Serum LDH levels were slightly higher on day 30, and significantly higher on day 60 in the unrelated, compared with the related group. Platelet counts on day 30 did not differ between the two groups. However, on day 60, platelet counts were significantly lower in the unrelated group. Serum fibrinogen levels were slightly lower in the unrelated donor group. Serum concentrations of CsA did not differ on day 30 between the two groups, but were significantly higher on day 60 in the unrelated group, because of the slowly tapering dose of CsA. Serum levels of aminotransferase, creatinine and urea nitrogen did not differ between the two groups. 
Rates of change in microangiopathic markers
No patient demonstrated increased FDPs in the related group on days 0 to 100 (Table 3) . Eight of 12 (66.7%) patients showed increased FDPs in the unrelated group. Four were diagnosed with thrombotic microangiopathy.
Duration and pattern of FDP elevation in unrelated BMT recipients
We analyzed the duration and pattern of FDP elevation in 12 recipients of unrelated donor BMT. Median period until onset of early elevation of FDPs was 30 days (range 26-34) for four cases. Six of 12 cases had a late onset of FDP elevation; median period 65 days (range 58-68). Two cases exhibited severe GVHD combined with severe hemolysis, and thrombocytopenia. One case was treated with highdose methylprednisolone on day 10, because of regimen related-toxicity. FDPs were not elevated, whereas a high level of D-dimer and consumption of fibrinogen, and thrombocytopenia persisted to day 100. We classified four types of FDP elevation in the unrelated group. Type 1 is elevation of FDP on day 30, accompanied by recovery of graft function (one case). Type 2 is elevation of FDP early (day 30) and/or late (day 65) (five cases). Type 3 is elevation of FDPs and D-dimer Table 3 Number of patients from related and unrelated donor groups with changes of microangiopathic markers levels on day 0, and severe GVHD or diffuse alveolar hemorrhage (two cases). Type 4 is elevation of FDPs or Ddimer associated with regimen related-toxicity before day 10 (one case).
Outcome of thrombotic microangiopathy
Four of 12 patients in the unrelated group were diagnosed with thrombotic microangiopathy. Central nervous system complications were observed in one case. The median period to diagnosis from BMT was 59 days (range 27-92). Three patients died with a median survival of 48 days of thrombotic microangiopathy (range 40-95), diffuse alveolar hemorrhage, acute GVHD, and systemic aspergillosis. One patient has survived 404 days. Three of eight thrombotic microangiopathy negative unrelated donor patients died of diffuse alveolar hemorrhage and GVHD. Four of 12 recipients of related donor BMT died with a median survival of 636 days (range 171-759). Three of these patients died of leukemia relapse and one of acute GVHD.
Discussion
Our findings show an increased incidence of microangiopathic changes in patients receiving unrelated donor HLA-matched bone marrow transplants. FDP elevation developed on day 30 in unrelated donor BMTs. The day when FDP first began to elevate after BMT was always followed by the day when the WBC count exceeded 1000/l. This reaction might be attributed to recovery of allograft function, especially of monocytes and lymphocytes. A highly significant correlation between the time of maximal monocyte count and time of minimal aPTT and fibrinogen has been reported. 18 This suggests microangiopathic changes as a result of cellular activation, and subsequent release of cytokines, IL-1, TNF, and ␥-IFN during GVHD.
Thus, we suspected that microangiopathic change on day 30 was associated with GVHD in unrelated donor BMT recipients, not prevented by CsA, short-course methotrexate and prednisone prophylaxis regimen. The causative factors proposed for microangiopathy include total body irradiation, active cytomegalovirus or fungal infection, CsA toxicity, and acute GVHD. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In our study, a TBI/AraC/CY preparative regimen was employed for unrelated donor BMT, and TBI/CY regimen for related donor BMT. Thus, we could not exclude the possibility of vascular endothelial damage caused by AraC. However, there has been no report of marked endothelial damage in patients treated with AraC. 19 Our case study suggests microangiopathic changes are not attributable to nephrotoxicity from CsA and total body irradiation on day 30.
Pettitt and Clark 4 classified four subtypes of thrombotic microangiopathy: multifactorial fulminant type, conditioning-associated HUS, CsA nephrotoxicity with microangiopathic hemolytic anemia and CsA neurotoxicity with microangiopathic anemia. 4 Microangiopathic changes in cases of unrelated donor BMT are considered to be of the multifactorial fulminant type, and are associated with acute GVHD.
A diagnosis of thrombotic microangiopathy after BMT is difficult to establish. 4 We consider FDP elevation to be an important first marker of thrombotic microangiopathy. The first FDP elevation at around day 30 is clearly associated with recovery of graft function, while the elevation on day 65 is multifactorial. We suspected that a high concentration of CsA and/or various infections, promotes endothelial damage and the development of thrombotic microangiopathy. Although it has been reported that low levels of ATIII and protein C predict multi-organ dysfunction syndrome in BMT, 20 we did not routinely examine ATIII and protein C.
No specific therapy has been established for thrombotic microangiopathy after BMT. Plasma exchange or high-dose cortisol therapy is reportedly effective in some cases. 11, 14, 19, 21 We administered high-dose methylprednisone, methotrexate, antifibrinolytics and fresh frozen plasma, platelets and concentrated red cells. However, the efficacy of these therapies was limited.
If a patient has elevated levels of FDPs and LDH, thrombocytopenia, and a decrease in fibrinogen, thrombotic microangiopathy should be ruled out, and an alternative immunosuppressive treatment such as corticosteroids or plasma exchange should be considered even without fulfillment of GVHD criteria. Correction of microangiopathic abnormalities may improve survival of BMT patients.
